BioTuesdays Feature Articles | Life Sciences News

Feature

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead to neurodegenerative...

September 24, 2019

Feature

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...

September 10, 2019

Feature

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Closely-held Interface Biologics is selling its Endexo surface modification business and shifting its focus to its Epidel drug delivery technology, initially for ophthalmic indications.

September 3, 2019

Feature

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Feature

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise...

August 20, 2019

Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...

August 12, 2019

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Feature

Stifel analyst discusses emerging NASH therapeutic space

As a director and senior analyst covering the biotechnology sector at Stifel, Derek Archila combines analytic ability and industry experience. He has held executive positions covering biotechnology and specialty...

July 12, 2019

Feature

Ocutrx augmented reality headset helping AMD patients see clearly

California-based Ocutrx Vision Technologies has developed an augmented reality (AR) headset that helps age-related macular degeneration (AMD) patients overcome severe and devastating vision loss.

July 9, 2019

Feature

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is transitioning from a development- to commercial-stage company as it rolls out its Health Canada-cleared PoNS medical device for the treatment of chronic balance...

July 2, 2019

Feature

Chardan president, Jonas Grossman, talks SPACs

By Abby Hardy As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide view...

June 25, 2019

Feature

Zenabis sets sights on becoming leading cannabis producer

By Len Zehr Despite being a new entrant in the cannabis market, Zenabis Global (TSX:ZENA) is making huge strides to become one of the largest licensed producers of medical and adult-use recreational cannabis in Canada...

June 11, 2019

Feature

Oragenics developing novel therapeutics using synthetic bacteria

By Abby Hardy Oragenics (NYSE American: OGEN) is leveraging its synthetic biology platforms to address two significant unmet medical needs: oral mucositis (OM) and multi drug-resistant (MDR) bacterial infections...

May 28, 2019

Feature

BriaCell advancing potential breakthrough immunotherapy for advanced breast cancer

By Len Zehr BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) has reported impressive early safety and efficacy data with its lead immunotherapies for the treatment of advanced breast cancer. “Right now, there is no...

May 21, 2019

Feature

MediXall transforming patient-healthcare provider experience

By Len Zehr MediXall Group (OTCQB:MDXL) has launched a new generation healthcare marketplace platform to address self-pay and high deductible consumers’ growing need for greater healthcare cost transparency and access...

May 14, 2019

Feature

Ceapro transitioning to biopharmaceutical company from contract manufacturer

By Len Zehr Ceapro (TSXV:CZO) is transitioning to a new business model – from a contract manufacturer to a biopharmaceutical company – to pursue multiple growth opportunities in nutraceuticals and...

May 7, 2019

Feature

Leviticus Cardio developing wireless system to drive VADs

Michael Zilbershlag, Co-Founder and CEO By Len Zehr Closely-held Leviticus Cardio of Israel is developing a wireless system capable of providing day-to-day power needs for implanted ventricular assist devices (VADs)...

April 30, 2019

Feature

In conversation with Susan Linna of BDO

Susan Linna, Managing Director Life Sciences Specialty Services at BDO By Len Zehr As managing director, life sciences specialty services at BDO, the global professional services firm, Susan Linna has more than 25 years...

April 23, 2019

Feature

CellMax developing first blood test for CRC preventative screening

Padma Sundar, VP of Strategy and Market Access By Len Zehr Closely-held CellMax Life has developed FirstSightCRC, the first blood test to identify precancerous adenomas, with accuracy similar to colonoscopies, when...

April 16, 2019

Feature

BioSig unlocking future of bioelectronic medicine through signal processing

Kenneth Londoner, Founder, Chairman and CEO By Len Zehr With the FDA’s 510(k) clearance of its PURE EP System in August 2018 and first successful patient cases, BioSig (NASDAQ:BSGM) is advancing its vision to improve...

April 9, 2019

Subscribe